Clinical Trial Update: Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating lenalidomide, thalidomide, and dexamethasone in relapsed or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Thalidomide (thalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-11-04